Clinical Trials Logo

Lymphoma, T-Cell, Peripheral clinical trials

View clinical trials related to Lymphoma, T-Cell, Peripheral.

Filter by:

NCT ID: NCT02987244 Recruiting - Clinical trials for T Cell Non-Hodgkin's Lymphoma

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide, epirubicin,vindesine, etoposide and prednisone) regimen as first line treatment in newly-diagnosed T-NHL.

NCT ID: NCT02953652 Completed - Clinical trials for Peripheral T-Cell Lymphoma (PTCL)

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Start date: November 2016
Phase: Phase 2
Study type: Interventional

Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL).

NCT ID: NCT02944812 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

Start date: March 2016
Phase: Phase 2
Study type: Interventional

This trial intends: 1.To evaluate the concentration of Chidamide in the serum and cerebral-spinal fluid of PTCL patients at certain time points after taking the medicine, to evaluate the pharmacokinetics of Chidamide in these patients and its CNS (central nervous system) distribution. 2. To evaluate the efficiency and safety of Chidamide in PTCL patients.

NCT ID: NCT02879526 Recruiting - Clinical trials for Relapse/Refratory Peripheral T Cell Lymphoma

Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma

Start date: August 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate efficacy and safety of Chidamide Combined With Cyclophosphamide,Prednisone,Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II,Single-arm,Open-label, Muti-center Study

NCT ID: NCT02856997 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.

NCT ID: NCT02809573 Completed - Clinical trials for Peripheral T-cell Lymphoma

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Start date: August 11, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chidamide in a range of doses combined with CHOP in fixed dose in patients with newly diagnosed peripheral T-cell lymphoma.

NCT ID: NCT02788916 Completed - Clinical trials for Lymphoma, T-Cell, Peripheral

A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas

Start date: September 25, 2015
Phase: N/A
Study type: Observational

The purpose of this study is to establish the distribution of peripheral T-cell lymphocyte (PTCL) subtypes by re-analysis and re-classification of samples according to the 2008 World Health Organization (WHO) classification of lymphoid neoplasms.

NCT ID: NCT02783625 Active, not recruiting - Lymphoma Clinical Trials

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Start date: May 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of a study drug called duvelisib.

NCT ID: NCT02753543 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Start date: November 2015
Phase: Phase 2
Study type: Interventional

This is a single arm, prospective trial to evaluate the efficacy and safety of Chidamide in combination with previous chemotherapy in peripheral T cell lymphoma patients who did not achieve complete response after 3 cycles of chemotherapy in interim evaluation.

NCT ID: NCT02742727 Recruiting - Clinical trials for Acute Myeloid Leukemia

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.